This week's story of two young Canadian brothers with cystic fibrosis reveals a bleak reality — only one has access to a promising new medication in a clinical trial, while a similar drug that could help his brother is too expensive. But access to the manufacturer's drugs is not just a problem in Canada. There are bitter fights in other jurisdictions over how much the company is charging.
Post a Comment